Droia Ventures

Droia Ventures is a Belgium-based venture capital firm that specializes in early-stage biotech investments, focusing exclusively on oncology and genetic diseases. With over €450 million under management, Droia supports young drug development companies that leverage cutting-edge science to bring breakthrough therapies to patients. Their portfolio includes companies such as Actio Biosciences and Vicinitas Therapeutics, which are focused on drug discovery in these high-impact areas. The firm’s investment strategy is highly targeted, aiming to fill the unmet medical needs in cancer treatment and genetic diseases like cystic fibrosis and hemophilia. Droia’s funds typically invest in newly founded or early-stage platform companies, often providing both financial backing and scientific expertise to help startups develop first-in-class drug candidates. Droia’s global reach is evident in its investments across the U.S. and Europe, with check sizes typically in the seed and early venture stages. Led by experienced partners like Janwillem Naesens and industry veteran George Golumbeski, Droia emphasizes long-term partnerships and active involvement in the scientific and business growth of its portfolio companies​.